NAD⁺-related Peptides

Overview

This page covers a small and heterogeneous research category: peptides and peptide-conjugate strategies that intersect with NAD⁺ biology — the cofactor at the centre of sirtuin signalling, PARP-mediated DNA damage response, and mitochondrial electron transport. The category includes peptides that modulate the NAD⁺ salvage pathway, peptide carriers that deliver NMN or other NAD⁺ precursors, and mitochondrially-targeted peptides whose net effect is preservation of cellular NAD⁺/NADH ratios under stress.

NAD⁺ itself is a small-molecule cofactor, not a peptide. The most-studied small-molecule NAD⁺ precursors — nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) — are nucleoside derivatives and fall outside the scope of this site. They are mentioned here only for context. The peptide entries below intersect with NAD⁺ biology through indirect mechanisms.

Because this category is heterogeneous, the structure of this page differs from the others on the site: it summarises the published peptide-side approaches to NAD⁺ modulation rather than presenting a single named compound. As with all research peptides, the entries below are research tools and have no licensed therapeutic use in the United Kingdom.

The broader NAD⁺ research field has matured rapidly since 2013, driven by Sinclair, Imai, Guarente and Auwerx group outputs on tissue NAD⁺ declines with age, the introduction of NMN and NR as orally bioavailable precursors, and the first generation of human supplementation trials in older-adult cohorts. Within this context, the peptide-side contribution is best understood as complementary rather than competitive — small-molecule precursors restore NAD⁺ substrate availability, while peptide-axis interventions either preserve mitochondrial NAD⁺/NADH balance under stress, allosterically modulate specific sirtuin isoforms, or improve tissue-selective delivery of co-administered precursors.

The reason this site covers the category at all — given the absence of any single named clinical-stage peptide product — is that the peptide-axis approach is the most likely route to selective intervention. Small-molecule precursor supplementation raises NAD⁺ globally and undirectedly; if the goal is restoration of, say, hepatic SIRT3 activity in a metabolic-syndrome research context, a peptide intervention selective for that compartment is in principle higher-resolution. Whether this principle survives translation into useful clinical tools remains the central open question.

Mechanism of action

Three intersecting peptide approaches exist in the published literature. The first is direct sirtuin modulation: short peptides have been designed as substrate mimetics or allosteric modulators of SIRT1, SIRT3 and SIRT6, although this work is largely preclinical and has not produced clinical-stage candidates. SIRT3-modulating peptides in particular are of interest for mitochondrial energetics.

The second is preservation of NAD⁺ levels through mitochondrial-membrane stabilisation. Peptides such as SS-31 (covered separately on this site) restore cristae structure and indirectly preserve NAD⁺/NADH balance in aged or stressed mitochondria. The effect is downstream of architecture preservation rather than direct enzymatic modulation, but the net consequence on NAD⁺-dependent biology is significant.

The third is conjugate-delivery strategies: peptide carriers used to improve cellular or tissue-selective delivery of small-molecule NAD⁺ precursors. This is an active research area but has not yet produced widely-available research-grade conjugate products.

Across all three approaches the underlying ageing-biology rationale is the same: NAD⁺ levels fall with age, sirtuin activity declines correspondingly, and restoration of NAD⁺ availability is hypothesised to recover sirtuin-dependent metabolic and DNA-repair programmes. Whether peptide-based strategies offer advantages over direct precursor supplementation is an open research question.

Direct sirtuin substrate-mimetic peptide work has focused on three isoforms with the clearest ageing-biology relevance: SIRT1 (nuclear, regulator of PGC-1α and FOXO transcription factors), SIRT3 (mitochondrial, regulator of fatty-acid oxidation and antioxidant defence enzymes), and SIRT6 (nuclear, chromatin-localised, regulator of telomere maintenance and DNA-damage response). Substrate-mimetic peptides for each isoform have been characterised crystallographically in collaboration with the Wolberger and Denu structural-biology groups, and these peptides have served as scaffolds for the design of allosteric modulators. The translation gap from structural probe to pharmacological tool is substantial and has not been closed.

MOTS-c provides an unexpected connection between the mitochondrially-derived peptide field and NAD⁺ biology. Under metabolic stress, MOTS-c translocates from mitochondria to the nucleus and binds chromatin at antioxidant-response-element regions (Kim et al. 2018, Cell Metabolism); among the genes it modulates are several within the NAMPT-dependent NAD⁺ salvage pathway. This positions MOTS-c — a peptide whose primary classification is mitokine — as an indirect NAD⁺-axis modulator, and provides a mechanistic link between mitokine biology and NAD⁺-biology research programmes that have historically operated on parallel tracks.

Research history

Peptide-based NAD⁺ modulation has been a niche thread within the broader NAD⁺ biology field. Major research milestones have been small-molecule rather than peptide: the work of Imai and Guarente identifying sirtuins as NAD⁺-dependent deacetylases (1999–2000), the Sinclair group's characterisation of NMN and NR as precursors capable of restoring tissue NAD⁺ (2013–2018), and clinical trials of NMN supplementation in human cohorts (2019 onward).

Peptide-side contributions have included synthesis of sirtuin-substrate mimetic peptides for structural studies, design of cell-penetrating peptide carriers for NAD⁺ precursor delivery, and characterisation of mitochondrial peptide effects on NAD⁺ pools. These threads remain preclinical.

Summarised studies